Insulet Corp

Insulet Corp’s Q4 earnings, due 18 Feb 2026, could boost revenue 28.7% and fuel growth plans amid a booming diabetes‑care market.

Insulet Corp has appointed Eric Benjamin as its new Chief Operating Officer, a strategic move aimed at strengthening the company’s operational backbone and driving growth in the competitive health care sector.

Insulet Corp reported a strong second quarter, with revenue surging 33% to $649 million, outpacing expectations and solidifying its position as a leader in the diabetes management market.

Insulet Corporation’s Q1 results show a mixed bag, but the company’s robust revenue growth and strategic expansions have led to a surge in its stock price and increased analyst confidence.

Insulet Corp reports strong Q1 2025 results, with 30% revenue growth driven by Omnipod system success, prompting a bullish market reaction and raised full-year revenue guidance.

Insulet Corp reports strong Q1 2025 performance with 30% revenue growth, raises full-year revenue guidance to 19-22%, and sees stock price surge amid investor confidence.

Insulet Corp reports a 30% increase in revenue for Q1 2025, driven by strong sales of its Omnipod system and international market expansion, with its stock price rising to $260.00.